ProCE Banner Activity

Experts Answer Pressing Questions on Recent Advances in Treatment of Relapsed/Refractory Multiple Myeloma

Clinical Thought
Multiple myeloma experts answer audience questions from a recent symposium on strategies for incorporating novel therapies for the treatment of relapsed or refractory multiple myeloma into clinical practice and managing toxicities with approved and investigational agents.

Released: August 18, 2022

Expiration: August 17, 2023

No longer available for credit.

Share

Faculty

Paul G. Richardson

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Natalie S. Callander

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Noopur Raje

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

GlaxoSmithKline

Janssen administered by Scientific Affairs

Karyopharm Therapeutics

Regeneron Pharmaceuticals, Inc.

Program Director Disclosure

Program Director

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Paul G. Richardson, MD: researcher: Bristol-Myers Squibb/Celgene, Karyopharm, Oncopeptides, Takeda; consultant: AstraZeneca, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Karyopharm, Novartis, Oncopeptides, Sanofi, Secura Bio, Takeda.

Faculty Disclosure

Primary Author

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Natalie S. Callander, MD, has no relevant financial relationships to disclose.

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Noopur Raje, MD: researcher: 2seventy bio; consultant/advisor/speaker: Amgen, Bristol-Myers Squibb, Bluebird, Caribou Biosciences Celgene, GlaxoSmithKline, Immuneel, Janssen, Merck, Millennium, Novartis, Pfizer, Sanofi, Takeda.